JEADV clinical practice最新文献

Basal cell carcinoma (BCC), which frequently occurs in sun-exposed areas of the head and neck region, is the most common cutaneous malignancy but the least studied with radiologic imaging techniques. This article outlines the case of a 65-year-old male with a pigmented BCC of the right shoulder discovered on positron emission tomography-computed tomography (PET/CT). The lesion was initially suspected as a melanoma. However, the histopathological features showed a tumor of basaloid cells. PET/CT is an excellent technique for the detection of hypermetabolic tumors, such as melanoma, squamous cell and Merkel cell carcinomas, in lymph nodes and distant organs. The usefulness of PET is limited for slowly growing tumors, such as BCC. However, PET/CT can be useful for the detection of distant metastasis in locally advanced BCC as well as in the follow-up of locally advanced BCC on Hedgehog inhibitors.

This retrospective case series examines the efficacy and safety of Bimekizumab in 22 patients with moderate to severe plaque psoriasis in a real-world clinical setting. The demographic and clinical characteristics of the participants, including a mean age of 43.7 years and a gender distribution of 60% male and 40% female, are summarised. Notably, 70% of the patients had previously received systemic therapy, and 50% had concurrent psoriatic arthritis. The evaluation over a 12-week treatment period revealed a significant reduction in psoriasis area and severity index scores from a baseline mean of 11.5−1.0 at Week 4 and further down to 0.3 by Week 12. Similar improvements were observed in body surface area, physician's global assessment and dermatology life quality index scores. Bimekizumab was well-tolerated with no reported adverse events, leading to no treatment discontinuations. These findings highlight the potential of Bimekizumab to provide rapid and sustained improvements in patients with moderate to severe plaque psoriasis, underlining its value in clinical practice.

Henoch–Schönlein purpura (HSP) is an immunoglobulin A (IgA)-mediated small-vessel vasculitis mostly observed in children and rarely in adults. It can affect many organs, mainly the skin, kidneys, joints, and gastrointestinal tract. We report a case of HSP occurring after COVID-19 vaccine (Pfizer-BioNTech).

Axillary hyperhidrosis and osmidrosis are challenging to treat, and neither topical nor systemic drugs have provided optimal treatment outcomes. In the past decades, treatment with botulinum toxin (BTX) has gained status as the gold standard, but it has its limitations both in regard to duration as well as indication for osmidrosis, specifically. A variety of local interventions have been explored in both the surgical field and within energy-based devices (EBDs) for alternative in-office treatments, but a collective overview is lacking. This study sought to investigate and assess the evidence on and effect of current local procedures for axillary hyperhidrosis and osmidrosis. A systematic search for prospective and controlled clinical trials in the databases PubMed, Embase and Cochrane Library until 31 December 2023 was executed. Relevant literature was identified independently by two authors according to predefined inclusion and exclusion criteria. Fifty-nine studies met the criteria for final inclusion, of which 46 studies were randomized controlled trials and 13 were nonrandomized trials. The included studies were classified by procedure type. Individually, a total of 28 studies investigated BTXs, 11 studies explored EBDs, while six studies reported on surgical interventions. Additionally, 14 studies evaluated alternative procedures or investigated combinations and side-by-side comparisons of the different procedure types. The dominant evidence on efficacy and safety was of BTX A. EBDs are increasingly being investigated with microwave thermolysis appearing to be the singular most established and scientifically well-founded method. In the surgical field, less-invasive methods are gaining ground. To meet the increasing demand for individualized treatment, additional high-quality comparative studies are required for the establishment of a future variety of standard treatments.

Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune-related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.